2-(4-chlorophenyl)-1H-imidazole-5-carboxylic acid | 34626-05-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-chlorophenyl)-1H-imidazole-5-carboxylic acid
• 英文别名: 2-(4-Chlor-phenyl)-imidazol-4-carbonsaeure；2-(4-chloro-phenyl)-1(3)H-imidazole-4-carboxylic acid
• CAS: 34626-05-6
• 化学式: C₁₀H₇ClN₂O₂
• 分子量: 222.631
• InChiKey: CWVVTDSOZJIEGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-chlorophenyl)-1H-imidazole-5-carboxylic acid 在 lithium aluminium tetrahydride 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 二异丙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 20.0h， 生成 2-(4-chlorophenyl)-1H-4-imidazolcarbaldehyde
  参考文献：
  名称：

  Synthesis, Structure, and Neuroprotective Properties of Novel Imidazolyl Nitrones

  摘要：

  A new series of imidazolyl nitrones spin traps has been synthesized and evaluated pharmacologically. The salient structural feature of these molecules is the presence of an imidazole moiety substituted by aromatic or heteroaromatic cycles. This connectivity imparts to the nitrone superior neuroprotective properties in vivo and in parallel reduced side effects and toxicity. Thus compound 6a (a 2-phenylimidazolyl nitrone) administered intraperitoneally protects (80%) mice from lethality induced by an intracerebroventricular administration of tert-butyl hydroperoxide (t-BHP) an oxidant capable of inducing neurodegenerative processes. Administration of the archetypal nitrone phenyl-tert-butyl nitrone (PBN) at an equimolar dose also affords some protection (60%) in this test. However, this activity is accompanied by hypothermia, whereas no such effect is apparent for 6a. Moreover, previously prepared nonsubstituted or alkyl-substituted imidazolyl nitrones were shown to be extremely toxic to rats in contrast to the compounds prepared in this study. The observed activities in vivo correlate well with the calculated partition coefficients (ClogP) and HOMO energy level.

  DOI：

  10.1021/jm991154w
• 作为产物：
  描述：

  2-(4-氯苯基)-4-三氟甲基-1H-咪唑 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以64%的产率得到2-(4-chlorophenyl)-1H-imidazole-5-carboxylic acid
  参考文献：
  名称：

  合成，抗病毒效力，体外ADMET和有效CD4模拟物的X射线结构，它们是针对HIV-1 gp120的Phe43腔的进入抑制剂。

  摘要：

  为了优化HIV-1进入前导拮抗剂NBD-11021，我们在本研究中提出了60种新类似物的合理设计和合成，并在单周期和多周期感染试验中确定了其抗病毒活性，从而得出了一种新的抗病毒药物。全面的结构－活动关系（SAR）。在针对一大批Env假型病毒的单周期分析中，与先导进入拮抗剂相比，其中两种化合物NBD-14088和NBD-14107在抗病毒活性方面显示出显着改善。相似化合物NBD-14010的X射线结构证实了新设计化合物的结合模式。这些化合物的体外ADMET谱与最有效的附着抑制剂BMS-626529相当，后者的前药目前正在接受III期临床试验。

  DOI：

  10.1021/acs.jmedchem.7b00179

文献信息

• Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120
  作者：Francesca Curreli、Young Do Kwon、Dmitry S. Belov、Ranjith R. Ramesh、Alexander V. Kurkin、Andrea Altieri、Peter D. Kwong、Asim K. Debnath

  DOI：10.1021/acs.jmedchem.7b00179

  日期：2017.4.13

  entry antagonist, NBD-11021, we present in this study the rational design and synthesis of 60 new analogues and determination of their antiviral activity in a single-cycle and a multicycle infection assay to derive a comprehensive structure–activity relationship (SAR). Two of these compounds, NBD-14088 and NBD-14107, showed significant improvement in antiviral activity compared to the lead entry antagonist

  为了优化HIV-1进入前导拮抗剂NBD-11021，我们在本研究中提出了60种新类似物的合理设计和合成，并在单周期和多周期感染试验中确定了其抗病毒活性，从而得出了一种新的抗病毒药物。全面的结构－活动关系（SAR）。在针对一大批Env假型病毒的单周期分析中，与先导进入拮抗剂相比，其中两种化合物NBD-14088和NBD-14107在抗病毒活性方面显示出显着改善。相似化合物NBD-14010的X射线结构证实了新设计化合物的结合模式。这些化合物的体外ADMET谱与最有效的附着抑制剂BMS-626529相当，后者的前药目前正在接受III期临床试验。
• [EN] BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVÉS DE BENZÈNESULFONAMIDE EN TANT QUE MODULATEURS TRAP1 ET UTILISATIONS ASSOCIÉES
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188880A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了Formula (I)的化合物及其药用盐、溶剂化合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记化合物和其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能在PTEN诱导激酶1（"PINK1"）功能丧失的情况下恢复活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，并/或减少活性氧自由基的产生。所提供的化合物还可能对α-突触核蛋白等聚集或错误折叠的蛋白进行重新折叠或溶解。本公开还提供了包含所提供化合物的药物组合物；包含所提供化合物或药物组合物的试剂盒；以及使用所提供化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• PYRAZOLE COMPOUND
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：US20140031406A1

  公开（公告）日：2014-01-30

  The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT 2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT 2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3 and R 4 are independently hydrogen or C 1-6 alkyl etc.; R 5 is C 4-7 alkyl or —(CR 8 R 9 ) r -E; R 6 , R 7 , R 8 and R 9 are independently hydrogen, fluorine or C 1-6 alkyl; A is C 6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C 3-8 cycloalkyl or C 6-10 aryl etc.; L is oxygen, sulfur or —NR 10 —; n is 1, 2 or 3; R 10 is hydrogen or C 1-6 alkyl etc.; and X is hydrogen or halogen etc.

  本发明涉及一种新型的血清素再摄取抑制剂，该剂还表现出5-HT2C拮抗作用（抗抑郁和抗焦虑作用），特别是5-HT2C反向激动剂作用，包括化合物（1）：或其药学上可接受的盐，其中R1、R2、R3和R4分别为氢或C1-6烷基等；R5为C4-7烷基或—(CR8R9)r-E；R6、R7、R8和R9分别为氢、氟或C1-6烷基；A为C6-10芳基或杂芳基等；r为1、2、3或4；E为C3-8环烷基或C6-10芳基等；L为氧、硫或—NR10—；n为1、2或3；R10为氢或C1-6烷基等；以及X为氢或卤素等。
• Pyrazole compound
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US10087146B2

  公开（公告）日：2018-10-02

  The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.

  本发明涉及一种新型血清素再摄取抑制剂，它还具有 5-HT2C 拮抗作用（抗抑郁和抗焦虑作用），特别是 5-HT2C 反激动作用，由化合物（1）组成： 或其药学上可接受的盐 其中R1、R2、R3和R4独立地为氢或C1-6烷基等；R5为C4-7烷基或-(CR8R9)r-E；R6、R7、R8和R9独立地为氢、氟或C1-6烷基； A 是 C6-10 芳基或杂芳基等；r 是 1、2、3 或 4；E 是 C3-8 环烷基或 C6-10 芳基等；L 是氧、硫或-NR10-；n 是 1、2 或 3；R10 是氢或 C1-6 烷基等； X 是氢或卤素等。
• HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR
  申请人：ASKA Pharmaceutical Co., Ltd.

  公开号：EP2594555B1

  公开（公告）日：2018-03-07